omeprazole has been researched along with citalopram in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (52.00) | 29.6817 |
| 2010's | 12 (48.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Li, Y; Li, YH; Wang, YH; Yang, L; Yang, SL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Malling, D; Poulsen, MN; Søgaard, B | 1 |
| Haataja, R; Huuhka, K; Leinonen, E; Riutta, A; Ylitalo, P | 1 |
| de Leon, J | 1 |
| Jerome, L | 1 |
| Andersson, M; Baldwin, RM; Bertilsson, L; Eliasson, E; Ingelman-Sundberg, M; Mwinyi, J; Ohlsson Rosenborg, S; Pedersen, RS; Sim, SC | 1 |
| Ferringer, T; Lountzis, NI; Puri, PK; Tyler, W | 1 |
| Barasain, MA; Sasich, LD; Sukkari, SR | 1 |
| Coelho, EB; Lanchote, VL; Rocha, A; Sampaio, SA | 1 |
| Bourke, J; Roper, S | 1 |
| Bagheri, H; Caillet, C; Chauvelot-Moachon, L; Montastruc, JL | 1 |
| Bibian, C; Constante, Y; Garcia-Arilla, E; Gil, J; Lozano, R; Quilez, RM | 1 |
| Dolkart, O; Gigi, R; Katzburg, S; Salai, M; Somjen, D; Yakobson, O | 1 |
| Charitos, C; Kapelios, CJ; Tsamatsoulis, M | 1 |
| Chen, YC; Chou, YC; Hung, CF; Ku, PM; Sun, CA; Tsai, CT; Wu, WT; You, SL | 1 |
2 review(s) available for omeprazole and citalopram
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19.
Topics: Alleles; Anti-Ulcer Agents; Antidepressive Agents, Tricyclic; Aryl Hydrocarbon Hydroxylases; Atomoxetine Hydrochloride; Citalopram; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Genetic Variation; Humans; Mixed Function Oxygenases; Omeprazole; Pharmacogenetics; Phenotype; Propylamines; Racial Groups | 2007 |
4 trial(s) available for omeprazole and citalopram
| Article | Year |
|---|---|
The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects.
Topics: Adolescent; Adult; Anti-Ulcer Agents; Cimetidine; Citalopram; Depressive Disorder; Drug Therapy, Combination; Female; Histamine H2 Antagonists; Humans; Male; Middle Aged; Omeprazole; Selective Serotonin Reuptake Inhibitors | 2005 |
The effect of CYP2C19 substrate on the metabolism of melatonin in the elderly: A randomized, double-blind, placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anticonvulsants; Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hydroxylases; Citalopram; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Lansoprazole; Male; Melatonin; Mental Disorders; Mixed Function Oxygenases; Omeprazole; Selective Serotonin Reuptake Inhibitors; Sleep Wake Disorders; Time Factors; Treatment Outcome | 2006 |
Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects.
Topics: Adult; Alleles; Anti-Ulcer Agents; Antidepressive Agents, Second-Generation; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Citalopram; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Female; Genotype; Humans; Male; Metabolic Clearance Rate; Middle Aged; Omeprazole; Substrate Specificity; Young Adult | 2008 |
Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Citalopram; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Humans; Male; Omeprazole; Selective Serotonin Reuptake Inhibitors; Young Adult | 2010 |
19 other study(ies) available for omeprazole and citalopram
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
Topics: Computational Biology; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Molecular Structure; Principal Component Analysis; Pyrrolizidine Alkaloids; Quantitative Structure-Activity Relationship; Reproducibility of Results; Substrate Specificity; Venlafaxine Hydrochloride | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Pregabalin-induced remission in a 62-year-old woman with a 20-year history of vulvodynia.
Topics: Amitriptyline; Analgesics; Anti-Ulcer Agents; Anticoagulants; Antidepressive Agents; Anxiety; Cardiotonic Agents; Cataract; Cataract Extraction; Cholecystectomy; Chronic Disease; Citalopram; Digoxin; Female; gamma-Aminobutyric Acid; Heart Failure; Humans; Hypertension; Hysterectomy; Lorazepam; Middle Aged; Mitral Valve Insufficiency; Omeprazole; Ovarian Neoplasms; Pain; Pregabalin; Sterilization, Tubal; Stomach Diseases; Vulvar Diseases | 2007 |
Hydroxychloroquine-induced hyperpigmentation: the staining pattern.
Topics: Aged; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin; Atorvastatin; Calcium Carbonate; Cardiomyopathy, Restrictive; Citalopram; Connective Tissue Diseases; Diuretics; Female; Furosemide; Glucosamine; Heptanoic Acids; Humans; Hydroxychloroquine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperpigmentation; Lupus Erythematosus, Systemic; Magnesium; Metolazone; Middle Aged; Naproxen; Omeprazole; Potassium Chloride; Prednisone; Pyrroles; Selective Serotonin Reuptake Inhibitors; Spironolactone | 2008 |
An academic perspective on the APPEs' educational significance.
Topics: Accreditation; Acetates; Citalopram; Cyclopropanes; Drug Labeling; Education, Pharmacy; Evidence-Based Medicine; Humans; Leukotriene Antagonists; Omeprazole; Practice Guidelines as Topic; Problem-Based Learning; Proton Pump Inhibitors; Quinolines; Schools, Pharmacy; Selective Serotonin Reuptake Inhibitors; Sulfides; United States | 2009 |
In with the new: the determinants of prescribing innovation by general practitioners in Ireland.
Topics: Age Factors; Androstenes; Citalopram; Drug Prescriptions; Drug Utilization; Ethinyl Estradiol; General Practitioners; Humans; Information Dissemination; Insurance Claim Review; Ireland; Lactones; Loratadine; Nicotine; Omeprazole; Practice Patterns, Physicians'; Residence Characteristics; Sulfones; Therapies, Investigational; Time Factors | 2012 |
Safety profile of enantiomers vs. racemic mixtures: it's the same?
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Cetirizine; Citalopram; Databases, Factual; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Stereoisomerism; Young Adult | 2012 |
Clinical relevance of the (S)-citalopram-omeprazole interaction in geriatric patients.
Topics: Aged; Citalopram; Cytochrome P-450 CYP2C19 Inhibitors; Electrocardiography; Female; Humans; Male; Omeprazole; Prospective Studies; Selective Serotonin Reuptake Inhibitors | 2014 |
Effects of commonly used medications on bone tissue mineralisation in SaOS-2 human bone cell line: an in vitro study.
Topics: Adrenergic beta-1 Receptor Antagonists; Bone and Bones; Calcification, Physiologic; Cell Line; Cell Proliferation; Citalopram; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Metformin; Metoprolol; Omeprazole; Osteoblasts; Proton Pump Inhibitors; Pyrimidines; Rosuvastatin Calcium; Selective Serotonin Reuptake Inhibitors; Sulfonamides | 2013 |
Hyperpyrexia in a patient with a left ventricular assist device: a diagnosis beyond the obvious.
Topics: Aged; Citalopram; Fever; Heart Failure; Heart-Assist Devices; Humans; Male; Omeprazole; Proton Pump Inhibitors; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome | 2018 |
Cardiovascular Outcomes Associated With Clinical Use of Citalopram and Omeprazole: A Nationwide Population-Based Cohort Study.
Topics: Cardiovascular Diseases; Citalopram; Death, Sudden, Cardiac; Drug Therapy, Combination; Female; Follow-Up Studies; Forecasting; Humans; Incidence; Male; Middle Aged; Omeprazole; Population Surveillance; Proton Pump Inhibitors; Retrospective Studies; Risk Assessment; Risk Factors; Selective Serotonin Reuptake Inhibitors; Survival Rate; Taiwan | 2019 |